Effectiveness of brentuximab vedotin before and after allogeneic stem‐cell transplantation in the management of transformed mycosis fungoides

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text

Medicine, Immunology, Oncology +15

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Nancy L. Bartlett, Robert Chen, Michelle A. Fanale et al. · Journal of Hematology & Oncology · 2014 · 180 citations · Full text

Medicine, Hematology, Oncology +15

Immunopathology of cutaneous T-cell lymphomas.

K Nasu, Jonathan W. Said, Eric C. Vonderheid et al. · PubMed · 1985 · 125 citations

Medicine, Dermatology, Immunology +12

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas

Maëlle Dumont, C. Ram‐Wolff, Marie Roelens et al. · British Journal of Dermatology · 2019 · 25 citations

Medicine, Oncology, Pharmacology +14